PLSE Pulse Biosciences Inc

Price (delayed)

$17.445

Market cap

$963.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$937.42M

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first ...

Highlights
The company's gross profit has surged by 100% YoY
The company's debt has shrunk by 88% YoY and by 2.7% QoQ
The quick ratio has declined by 11% year-on-year but it has increased by 3.9% since the previous quarter
The company's revenue has shrunk by 100% YoY
PLSE's equity is down by 18% since the previous quarter

Key stats

What are the main financial stats of PLSE
Market
Shares outstanding
55.23M
Market cap
$963.41M
Enterprise value
$937.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
26.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$43.51M
EBITDA
-$42.31M
Free cash flow
-$36.34M
Per share
EPS
-$0.81
Free cash flow per share
-$0.66
Book value per share
$0.66
Revenue per share
$0
TBVPS
$0.81
Balance sheet
Total assets
$49.16M
Total liabilities
$12.88M
Debt
$8.9M
Equity
$36.29M
Working capital
$30.77M
Liquidity
Debt to equity
0.25
Current ratio
7.06
Quick ratio
6.87
Net debt/EBITDA
0.61
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-68.3%
Return on equity
-88%
Return on invested capital
-311.9%
Return on capital employed
-98.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLSE stock price

How has the Pulse Biosciences stock price performed over time
Intraday
3.72%
1 week
-9.52%
1 month
62.43%
1 year
162.33%
YTD
42.52%
QTD
55.9%

Financial performance

How have Pulse Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.63M
Net income
-$42.55M
Gross margin
N/A
Net margin
N/A
The company's gross profit has surged by 100% YoY
The company's revenue has shrunk by 100% YoY
The net income has increased by 17% year-on-year
The operating income has grown by 11% year-on-year but it has declined by 2.4% since the previous quarter

Growth

What is Pulse Biosciences's growth rate over time

Valuation

What is Pulse Biosciences stock price valuation
P/E
N/A
P/B
26.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PLSE's EPS is up by 43% year-on-year and by 8% since the previous quarter
The P/B is 175% above the last 4 quarters average of 9.3 and 133% above the 5-year quarterly average of 11.0
PLSE's equity is down by 18% since the previous quarter
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Pulse Biosciences business performance
The ROIC has dropped by 118% since the previous quarter
PLSE's return on equity has surged by 93% year-on-year and by 24% since the previous quarter
The ROA has contracted by 9% from the previous quarter but it has grown by 8% YoY

Dividends

What is PLSE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLSE.

Financial health

How did Pulse Biosciences financials performed over time
The total liabilities has plunged by 84% YoY and by 13% from the previous quarter
The company's total assets fell by 30% YoY and by 17% QoQ
The company's debt is 75% lower than its equity
The debt to equity has soared by 104% YoY and by 19% from the previous quarter
The company's debt has shrunk by 88% YoY and by 2.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.